Published online Feb 16, 2023. doi: 10.12998/wjcc.v11.i5.1058
Peer-review started: December 5, 2022
First decision: December 26, 2022
Revised: January 4, 2023
Accepted: January 16, 2023
Article in press: January 16, 2023
Published online: February 16, 2023
Processing time: 70 Days and 21.1 Hours
The incidence of thyroid cancer has increased worldwide over the past four decades, and thyroid cancer is the most common endocrine cancer. The discovery of new biomarkers for thyroid cancer has significantly improved the understanding of the molecular pathogenesis of thyroid cancer, thus allowing more personalized treatments for patients with thyroid cancer.
Thyroid-stimulating hormone is the major regulator and growth factor of the thyroid. However, the role of thyroid-stimulating hormones in thyroid cancer still needs further exploration.
The aim of this study is to examine the relationship between thyroid-stimulating hormone and thyroid cancer.
75 patients with thyroid cancer were collected as the observation group and 50 healthy people as the control group. The control group was treated with thyroid replacement and the observation group was treated with thyroid-stimulating hormone inhibition. The levels of soluble interleukin (IL)-2 receptor (sIL-2R), IL-17, IL-35, free triiodothyronine (FT3), free tetraiodothyronine (FT4), CD3+, CD4+, CD8+, CD44V6, and tumor supplied group of factor (TSGF) were observed in the two groups.
After 4 wk of treatment, the levels of sIL-2R and IL-17 in the observation group were lower than those in the control group, while the levels of IL-35 were higher than those in the control group, with a statistically significant difference (P < 0.05). The levels of FT3, FT4, CD3+ and CD4+ in the observation group were higher than those in the control group, and the levels of CD8+, CD44V6, and TSGF in the observation group were lower than those in the control group.
Thyroid-stimulating hormone inhibition therapy, as the best treatment method for thyroid cancer, can slow down the condition of patients and is worthy of clinical promotion.
Thyroid-stimulating hormone is considered a risk factor for thyroid cancer, and thyroid hormone suppression therapy can reduce and control the progression of thyroid cancer. However, the effect of serum thyroid stimulating hormone may depend on the histological type of thyroid cancer. Therefore, in future research, we should focus on exploring the relationship between thyroid-stimulating hormones and different histological types of thyroid cancer.